Table 1.
Overall populationa, baseline demographic data and disease characteristics in the overall population
| Parameter | Overall patients (N = 569) | New abatacept users (n = 134) | Continuous abatacept users (n = 435) | P values (new vs continuing users) |
|---|---|---|---|---|
| Duration of abatacept therapy at enrolment, years, median (Q1, Q3) | 0.5 (0.1, 1.5) | 0.0 (0.0, 0.0) | 0.9 (0.4, 2.0) | <0.0001h |
| Patients with prior abatacept useb, n (%) | 493 (86.6)c | 58 (43.3) | 435 (100.0) | |
| Patients already receiving abatacept at baselined, n (%) | 567 (99.6)e | 134 (100.0) | 433 (99.5) | |
| Categories of overall observation time, years, n (%) | 0.0002i | |||
| ≤1 | 172 (30.2) | 57 (42.5) | 115 (26.4) | |
| >1 to ≤2 | 137 (24.1) | 36 (26.9) | 101 (23.2) | |
| >2 to ≤7 | 259 (45.5) | 41 (30.6) | 218 (50.1) | |
| >7 to 10 | 1 (0.2) | 0 0 | 1 (0.2) | |
| Overall observation, years, median (Q1, Q3) | 1.9 (0.8, 3.3) | 1.2 (0.5, 2.1) | 2.0 (1.0, 3.7) | <0.0001h |
| Patient-years of observation in study | 1214.6 | 204.7 | 1009.9 | |
| Baseline characteristics | ||||
| Age at enrolment, years, median (Q1, Q3) | 13.6 (10.7, 16.0) | 13.1 (10.2, 16.3) | 13.6 (10.9, 15.9) | 0.5818h |
| Age group at enrolment, years, n (%) | 0.0135i | |||
| 2–5f | 21 (3.7) | 9 (6.7) | 12 (2.8) | |
| 6–12 | 223 (39.2) | 57 (42.5) | 166 (38.2) | |
| 13–18 | 313 (55.0) | 68 (50.7) | 245 (56.3) | |
| >18 | 12 (2.1) | 0 (0.0) | 12 (2.8) | |
| Female, n (%) | 454 (79.8) | 110 (82.1) | 344 (79.1) | |
| Disease duration at enrolment, years, mean (S.D.) | 5.5 (3.8) | 5.0 (4.0) | 5.7 (3.8) | 0.0334h |
| Active joints (ACR definition), median (Q1, Q3) | 1.0 (0.0, 3.0) | 3.0 (1.0, 8.0) | 0.0 (0.0, 2.0) | <0.0001h |
| Joints with a limited range of movement, median (Q1, Q3) | 1.0 (0.0, 4.0) | 2.0 (1.0, 10.0) | 0.0 (0.0, 2.0) | <0.0001h |
| Physician Global Assessment of Disease Activity, VAS 0–10, median (Q1, Q3) | 1.0 (0.0, 3.0) | 3.8 (2.0, 5.0) | 1.0 (0.0, 2.0) | <0.0001h |
| Uveitis, n (%) | ||||
| History of uveitis (past and present) | 77 (13.5) | 24 (17.9) | 53 (12.2) | |
| Active uveitis at time of enrolment | 29 (5.1) | 14 (10.5) | 15 (3.5) | |
| JIA categories, n (%) | 0.0008i | |||
| Polyarticular RF− | 289 (50.8) | 62 (46.3) | 227 (52.2) | |
| Oligoarticular | 134 (23.6) | 40 (29.9) | 94 (21.6) | |
| Polyarticular RF+ | 54 (9.5) | 12 (9.0) | 42 (9.7) | |
| Undifferentiated | 33 (5.8) | 3 (2.2) | 30 (6.9) | |
| PsA | 26 (4.6) | 4 (3.0) | 22 (5.1) | |
| Enthesitis-related | 20 (3.5) | 12 (9.0) | 8 (1.8) | |
| Systemic | 13 (2.3) | 1 (0.8) | 12 (2.8) | |
| JIA-related medication (prior to and/or at baseline), n (%) | 523/558 (93.7) | 122/131 (93.1) | 401/427 (93.9) | |
| MTX | 523/558 (93.7) | 122/131 (93.1) | 401/427 (93.9) | |
| NSAIDs | 249/558 (44.6) | 46/131 (35.1) | 203/427 (47.5) | |
| Systemic steroids | 41/558 (7.4) | 6/131 (4.6) | 35/427 (8.2) | |
| LEF | 57/558 (10.2) | 10/131 (7.6) | 47/427 (11.0) | |
| SSZ | 37/558 (6.6) | 8/131 (6.1) | 29/427 (6.8) | |
| Adalimumabg | 224/558 (40.1) | 77/131 (58.8) | 147/427 (34.4) | |
| Etanercept | 267/558 (47.9) | 67/131 (51.2) | 200/427 (46.8) |
Patient-time of follow-up stratified by duration of abatacept treatment at registry entry.
For prior abatacept use, any patient whose first abatacept dose was on or after baseline was included.
Two patients took abatacept prior to baseline visit but were not on abatacept at baseline.
For patients already receiving abatacept at baseline, any patient taking abatacept at baseline where it was not the first dose was included.
All 569 patients had used abatacept prior to baseline, but two patients were not taking abatacept at the baseline visit.
Data are from real-world settings, as treatment was administered at the physician’s discretion.
One patient with PsA was receiving abatacept and adalimumab simultaneously.
Mann–Whitney U test.
Fisher’s exact test.
Q1: first quartile; Q3: third quartile; VAS: visual analogue scale.